Chronic kidney disease (CKD) and Depression
Conditions
Interventions
CKD combined with depression Western medicine group:Basic therapy for CKD + Escitalopram
CKD combined with depression Chinese herbal medicine group:Basic therapy for CKD + Chaihu Longgu Muli decoction with modified ingredients
Sponsors
Chongqing Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The diagnostic criteria for CKD are based on the "KDIGO-CKD Guidelines" published by the International Kidney Disease Organization in 2012. CKD staging is determined using the eGFR calculation formula (China's MDRD formula) (Part I of the trial). The diagnostic criteria for depressive disorders comply with the diagnostic criteria for depressive disorders in the Chinese Classification and Diagnostic Criteria for Mental Disorders (CCMD-3) (Part II). 2. Patients voluntarily participate in the study and provide informed consent by signing the informed consent form. 3. Patients are able to understand the research procedures and comply with them throughout the study duration. 4. Age range between 18-70 years. 5. During the screening period (within 30 days after signing the informed consent), the GFR fluctuation range in the past 3 months is =30%.
Exclusion criteria
Exclusion criteria: 1. Unable to provide informed consent. 2. Pregnant or lactating women. 3. NYHA III or IV heart failure, which means having underlying heart disease, significant limitation in physical activity, and experiencing fatigue, palpitations, dyspnea, or angina symptoms even at rest or with minimal exertion. 4. Liver dysfunction or cirrhosis; HIV infection or AIDS. 5. Underwent chemotherapy or alkylating agent treatment for malignant tumors in the past 2 years. 6. Received immunosuppressive therapy for primary kidney disease or systemic diseases in the past 3 months. 7. Previously diagnosed with genetic kidney diseases such as polycystic kidney disease. 8. Presence of infectious diseases or use of anti-infective treatment in the past 2 weeks. 9. Severe depression/suicidal tendencies, as there may be safety concerns with only herbal intervention. 10. Suspected or known allergy to any component of traditional Chinese medicine or escitalopram.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Rating Scale, Mental State Examination Scale, Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, Monocyte, Beck Depression Inventory.; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome scores;IFN-?\IL-1ß\IL-1RA\IL-2\IL-4\IL-5\IL-6\IL-7\IL-8\IL-9\IL-10\IL-12 p70\IL-13\IL-15\IL-17A\IL-18;G-CSF\GM-CSF\CD40L\MCP-1\MIP-1ß\TNF-a?TNF-ß\sTNFR2\CCL11\CXCL4\CXCL7\CXCL10;Montgomery-Åsberg Depression Rating Scale\Clinical Global Impression Scale\Quality of Life Assessment Scale;CD68\CD80\CD206\CD4\CCR7\CD45RA\CXCR5\FOXP3\CD25\CD3\CD4\TCRaß; | — |
Countries
China
Contacts
Public ContactLI Fan
Chongqing Traditional Chinese Medicine Hospital
Outcome results
None listed